Journal article
Developing Biomarkers and Methods of Risk Stratification: Consensus Statements from the International Kidney Cancer Symposium North America 2024 Think Tank
Urologic oncology, Vol.43(11), pp.639-653
11/2025
DOI: 10.1016/j.urolonc.2025.07.020
PMID: 40820078
Abstract
•Consensus statements developed on kidney cancer biomarker and risk stratification research priorities•40 kidney cancer experts convened to develop 19 consensus statements•Reviews kidney cancer research challenges and potential solutions
: Accurate prognostication and personalized treatment selection remain major challenges in kidney cancer. This consensus initiative aimed to provide actionable expert guidance on the development and clinical integration of prognostic and predictive biomarkers and risk stratification tools to improve patient care and guide future research.
: A modified Delphi method was employed to develop consensus statements among a multidisciplinary panel of experts in urologic oncology, medical oncology, radiation oncology, pathology, molecular biology, radiology, outcomes research, biostatistics, industry, and patient advocacy. Over three rounds, including an in-person meeting 20 initial statements were evaluated, refined, and voted on. Consensus was defined a priori as a median Likert score ≥8.
: Nineteen final consensus statements were endorsed. These span key domains including biomarker prioritization (favoring prognostic biomarkers), rigorous methodology for subgroup and predictive analyses, the development of multi-institutional prospective registries, incorporation of biomarkers in trial design, and improvements in data/biospecimen access. The panel also identified high-priority biomarker types (e.g., AI-based image analysis, ctDNA) for future research.
: This is the first consensus statement specifically focused on biomarker and risk model development for kidney cancer using a structured Delphi process. The recommendations emphasize the need for rigorous methodology, collaborative infrastructure, prospective data collection, and focus on clinically translatable biomarkers. The resulting framework is intended to guide researchers, cooperative groups, and stakeholders in advancing personalized care for patients with kidney cancer.
Details
- Title: Subtitle
- Developing Biomarkers and Methods of Risk Stratification: Consensus Statements from the International Kidney Cancer Symposium North America 2024 Think Tank
- Creators
- Daniel D. Shapiro - William S. Middleton Memorial Veterans HospitalEdwin Jason Abel - University of Wisconsin–MadisonLaurence Albiges - Institut Gustave RoussyDena Battle - Kidney Cancer Research Alliance, Alexandria, VA, USAStephanie A. Berg - Dana-Farber Cancer InstituteMatthew T. Campbell - The University of Texas MD Anderson Cancer CenterDavid Cella - Northwestern UniversityKatie Coleman - Chromophobe and Oncocytic Tumor Alliance, Austin, TX, USABenjamin Garmezy - Sarah CannonDaniel M. Geynisman - Fox Chase Cancer CenterTasha Hall - ExelixisElizabeth P. Henske - Brigham and Women's HospitalEric Jonasch - The University of Texas MD Anderson Cancer CenterJose A. Karam - The University of Texas MD Anderson Cancer CenterSalvatore La Rosa - Kidney Cancer AssociationBradley C. Leibovich - Mayo Clinic in ArizonaJodi K. Maranchie - University of PittsburghViraj A. Master - Emory UniversityBenjamin L. Maughan - University of UtahBradley A. McGregor - Dana-Farber Cancer InstitutePavlos Msaouel - The University of Texas MD Anderson Cancer CenterSumanta K. Pal - City Of Hope National Medical CenterJose Perez - ExelixisElizabeth R. Plimack - Fox Chase Cancer CenterSarah P. Psutka - University of WashingtonIrbaz B. Riaz - Mayo ClinicBrian I. Rini - Vanderbilt UniversityBrian Shuch - University of California, Los AngelesM. Celeste Simon - University of PennsylvaniaEric A. Singer - The Ohio State UniversityAndrew Smith - St. Jude Children's Research HospitalMichael Staehler - Ludwig-Maximilians-Universität MünchenChad Tang - The University of Texas MD Anderson Cancer CenterNizar M. Tannir - The University of Texas MD Anderson Cancer CenterUlka Vaishampayan - University of MichiganMartin H. Voss - Memorial Sloan Kettering Cancer CenterYousef Zakharia - Mayo Clinic in FloridaQing Zhang - The University of Texas Southwestern Medical CenterTian Zhang - The University of Texas Southwestern Medical CenterMaria I. Carlo - Memorial Sloan Kettering Cancer Center
- Resource Type
- Journal article
- Publication Details
- Urologic oncology, Vol.43(11), pp.639-653
- DOI
- 10.1016/j.urolonc.2025.07.020
- PMID
- 40820078
- NLM abbreviation
- Urol Oncol
- ISSN
- 1078-1439
- eISSN
- 1873-2496
- Publisher
- Elsevier Inc
- Grant note
- Exelixis
The 2024 IKCS North America think tank was supported with a sponsorship by Exelixis.
- Language
- English
- Electronic publication date
- 08/16/2025
- Date published
- 11/2025
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984948047702771
Metrics
2 Record Views